Laboratorios Farmaceuticos Rovi (ROVI) CMD 2025 summary

Strategic vision and growth pillars

• Targeting 1.5x–1.8x operating revenue growth by 2030 versus 2024, with CDMO revenue expected to double to around €700 million and specialty pharma to grow at a low single-digit rate, led by Okedi® and international expansion.

• Focus on three pillars: CDMO business, specialty pharma, and ISM technology platform, aiming for global leadership in complex injectables and long-acting therapies by 2030.

• Significant investments in manufacturing capacity, vertical integration, and new product launches to drive long-term growth, including expansion of sterile fill and finish capacity and new filling formats.

• R&D pipeline includes Letrozole SIE (quarterly injectable for breast cancer) and quarterly Risperidone, both entering Phase III trials in late 2025, leveraging proprietary ISM® technology.

• ESG strategy underpins operations, with improved ESG rating, a sustainability committee, and a 2023–2025 plan focused on supply chain responsibility and R&D partnerships.

CDMO business outlook and evolution

• CDMO market expected to grow at 7% CAGR, with injectable fill and finish segment at 10% CAGR through 2031; ROVI's CDMO revenues grew from €92 million in 2020 to €336 million in 2024.

• CDMO business expanding to 12 aseptic filling lines by 2026, with capacity for up to 810 million prefilled syringes, 180 million vials, and 110 million cartridges.

• Long-term contracts with over 30 blue-chip customers, including major agreements with top-five pharma companies and Moderna for mRNA products through 2032.

• Strategic investments of €85 million (2020–2024) and further CAPEX planned to address market shortages and demand for high-value injectables.

• Utilization rates expected to rise to 70–75% by 2030 as new lines become operational and market imbalance persists.

Specialty pharma and product portfolio

• Okedi® (Risperidone ISM®) sales doubled to €29 million in 2024, with global peak sales targeted at €100–200 million; launches planned in new countries.

• Low molecular weight heparin franchise (bemiparin and enoxaparin) generated €242 million in 2024, marketed in over 60 countries, with vertical integration via Glicopepton JV operational by 2026.

• Bemiparin achieved 31% market share in Spain and €96 million in 2024 revenue, with international growth as a key driver.

• Specialty pharma franchise includes over 20 licensed products, a strong sales force, and international expansion through six affiliates and joint marketing agreements.

• Specialty pharma expected to grow at low single digits, factoring in patent expirations and price erosion for key products like Neparvis.